Alcohol and cancer: the IARC position
When alcohol comes up in conversations about cancer risk, the responses are often polarised. Some cite the so-called French paradox — the observation that red wine, because it contains resveratrol, might be protective. Others point to studies suggesting that moderate drinking, particularly wine, is associated with cardiovascular benefits. And then there’s the person in the room who mentions one study suggesting that abstainers have higher all-cause mortality than light drinkers, as if that settles the matter.
None of these arguments hold up under scrutiny. The evidence on alcohol and cancer is, in fact, unusually clear — clearer than almost any other dietary factor we cover in this series. The International Agency for Research on Cancer (IARC), the gold standard body for evaluating cancer-causing substances, classifies alcohol as a Group 1 carcinogen: definitely causes cancer in humans, at any dose.
What the IARC classification actually means
Group 1 is IARC’s highest classification. It means there is sufficient evidence in humans that the substance causes cancer. Alcohol shares this classification with tobacco, asbestos, and processed meat. That doesn’t mean a glass of wine is equivalent to smoking a cigarette — dose matters enormously — but it does mean that the carcinogenicity of alcohol in humans is not in question.
A comprehensive review published in Nutrients in 2022 (DOI: 10.3390/nu14091954) examined alcohol consumption, drinking patterns, and chronic disease risk. The evidence is consistent across multiple cancer types: breast, colorectal, liver, oesophageal, oral cavity, pharynx, and larynx cancers are all causally linked to alcohol consumption. For breast cancer specifically — highly relevant to many readers of this series — even low levels of drinking are associated with a measurable increase in risk.
The mechanisms are well established. Alcohol is metabolised to acetaldehyde, a toxic compound that directly damages DNA and impairs the cellular repair mechanisms that would normally catch and correct that damage. Alcohol also raises circulating oestrogen levels — relevant to hormone-sensitive cancers — disrupts folate metabolism (folate being essential for DNA synthesis and repair), and generates reactive oxygen species that contribute to oxidative stress and inflammation.
Debunking the resveratrol argument
The resveratrol hypothesis — that a polyphenol found in red wine might be protective enough to offset alcohol’s carcinogenic effects — has been thoroughly examined and largely dismissed in the human evidence. Resveratrol is poorly absorbed in humans, metabolised rapidly, and the concentrations achievable through wine consumption are far below those that produce effects in laboratory studies. The doses used in cell and animal studies bear no relation to what a human absorbs from a glass of red wine.
More fundamentally, large-scale prospective cohort studies have not found that red wine drinkers have better cancer outcomes than those who drink other forms of alcohol. When alcohol consumption is controlled for, the type of drink is not the determining variable. The carcinogen is the ethanol, not the vessel it arrives in.
What about the “J-curve” and cardiovascular benefits?
The observation that light-to-moderate drinkers appear to have lower cardiovascular mortality than abstainers — the so-called J-curve — has been substantially reappraised in recent years. Much of this apparent benefit is now attributed to confounding: abstainers often include former drinkers who stopped for health reasons, people on medications that preclude drinking, and those with pre-existing illness. When these groups are properly accounted for, the protective effect of alcohol largely disappears.
Even if a modest cardiovascular benefit did exist for some individuals, it would need to be weighed against the well-established cancer risk. Given that cancer is now the leading cause of death in the UK for people under 75, and given that alcohol contributes to cancers of the breast, bowel, liver, and throat, this trade-off calculation is not straightforward — and it is not one that any regulatory body currently endorses.
What this means in practice
The honest position — the one that reflects the actual evidence — is that there is no safe level of alcohol consumption from a cancer risk perspective. That doesn’t mean a single drink is catastrophically dangerous. Risk is cumulative, dose-dependent, and interacts with individual factors including genetics, sex, body composition, and dietary patterns. But it does mean that the idea of a “safe” or “protective” amount of alcohol is not supported by the current evidence.
For practical purposes:
If you drink, less is better. The dose-response relationship is fairly linear for most alcohol-related cancers — each drink adds incremental risk. Reducing consumption from, say, 14 units a week to seven is genuinely meaningful, even if it doesn’t bring risk to zero.
Alcohol-free days matter. Giving the body time to clear acetaldehyde and recover liver function reduces cumulative exposure. This is not about abstinence as a moral position; it’s about biology.
Context matters for breast cancer specifically. The evidence linking alcohol to breast cancer is particularly robust, and the association is present even at low levels of consumption. For women with a personal or family history of breast cancer, or those with other risk factors such as dense breast tissue or hormonal factors, the calculus here is especially worth discussing with a clinician.
Folate helps partially offset risk. The interaction between alcohol and folate is one of the better-studied aspects of this topic. Adequate dietary folate — from leafy greens, legumes, and whole grains — appears to partially mitigate some of the DNA-damaging effects of alcohol. This is not a licence to drink more; it’s a practical observation about dietary synergy.
What the evidence does not yet show
We don’t have large randomised controlled trials of alcohol reduction and cancer incidence — for the obvious reason that it would be unethical to randomise people to drink alcohol as part of a trial once causality has been established. The evidence base is therefore primarily large prospective cohort studies, case-control studies, and the mechanistic work that explains why the association exists. This is strong evidence — stronger than for many dietary factors — but it is worth being transparent about the study design limitations.
We also don’t yet have a complete understanding of why some heavy drinkers don’t develop alcohol-related cancers whilst others do. Genetic factors — particularly variants in alcohol dehydrogenase genes that affect how quickly acetaldehyde is cleared — likely play a role, but this area of personalised medicine is still developing.
The bottom line
Alcohol is a Group 1 carcinogen. The IARC position is unambiguous, and the mechanistic evidence explains why. There is no reliable evidence that any form or amount of alcohol is protective against cancer, and the resveratrol argument does not hold up in human populations. If reducing cancer risk is a priority, reducing alcohol consumption — or eliminating it — is one of the clearest, most evidence-backed steps available. This is not a comfortable message, but it is an honest one.
Scientific references
- Alcohol, drinking pattern, and chronic disease risk. Nutrients, 2022. DOI: 10.3390/nu14091954. IARC classifies alcohol as a Group 1 carcinogen.
This article is written for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, prevent, or cure any medical condition, including cancer. If you have a cancer diagnosis or are undergoing treatment, please discuss any lifestyle or dietary changes with your oncologist or medical team before making them. The studies cited reflect current research at the time of writing; the field is evolving rapidly and findings may be updated or superseded. Chloe Archard is a nutritional health coach, not a medical doctor.
